Azithromycin and steroids
Phase 1Small molecule
Azithromycin and steroids is one of 41 small molecule programs targeting Nephrotic Syndrome. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
74 competitors in Nephrotic Syndrome
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Neoral
NovartisApproved
Lovenox
SanofiApproved
Thalitone
Alnylam PharmaceuticalsApproved
Rayos
RRoxane Laboratories
Approved
Rituxan
RochePhase 3
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Decadron
AAspen Global Incorporated
Approved
Bumex
VValidus Pharmaceuticals
Approved
Cellcept
NovartisPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Nephrotic Syndrome1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Azithromycin and steroids. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details